The Oxford-Harrington Rare Disease Centre initiates first disease priority area: Friedreich’s Ataxia

27 May 2021, The Oxford-Harrington Rare Disease Centre is redoubling efforts to develop a therapeutics programme for Friedreich’s Ataxia.

OHC will be building on the long history of important contributions to the FA field by Oxford researchers. As a first step in this new journey, with the support of EndFA, a philanthropic partner focused on FA, the OHC has recruited a new Research Facilitator in Friedreich’s Ataxia. Dr Geoffrey Denwood joined the OHC at the University of Oxford site in April 2021, and will dedicate his time and expertise into coordinating the activities of the OHC in FA. Dr Denwood will evaluate the current status of FA translational research and therapeutics development locally and globally, then work to fund and implement an OHC programme harnessing the best expertise and most promising therapeutic opportunities.